Clinical Trials Directory

Trials / Unknown

UnknownNCT02838576

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women: a Randomized, Double-blind Controlled Trial

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Hospital de Clinicas de Porto Alegre · Academic / Other
Sex
Female
Age
45 Years – 55 Years
Healthy volunteers
Accepted

Summary

Arthralgia has been a common complaint in postmenopausal period which seems to be involved with estrogen depletion, although, its pathophysiology isn´t completely clarified. It seems to relate with the level of physical activity, climacteric symptoms and pain catastrophizing. In view of the multiple dimensions involved in arthralgia in postmenopausal women which characterize it as a complex phenomenon, this study aims to describe the effects of hormone replacement therapy in women aged between 45 and 55 years, considering estrogen as a possible anti-nociceptive factor.

Detailed description

This study is a randomized double-blind controlled clinical trial with postmenopausal women aged between 45 and 55 years with chronic arthralgia related to climacteric. They will be evaluated climacteric symptoms, pain intensity, level of physical activity, pain catastrophising, depression, anxiety, quality of sleep and quality of life. The volunteers will be randomized, in the proportion 1:1, to treatment with either 0,625 mg conjugated equine estrogen, via oral administration, for 12 weeks or placebo, via oral administration, for 12 weeks. The randomization will be performed by a computer-generated random numbers list. The investigators will be blinded until completion of 12 weeks. Evaluation of climacteric symptoms, pain intensity, level of physical activity, pain catastrophising, depression, anxiety, quality of sleep and quality of life will be performed in the hospital at baseline, 1, 2, 3, 6 months and 15 days. In each visit, participants will be evaluated about adverse effects such as diarrhea, nausea and vomit.

Conditions

Interventions

TypeNameDescription
DRUGConjugated Equine EstrogenUse of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
DRUGPlaceboUse of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.

Timeline

Start date
2017-03-01
Primary completion
2019-12-02
Completion
2020-12-31
First posted
2016-07-20
Last updated
2019-10-14

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT02838576. Inclusion in this directory is not an endorsement.